Clearmind Medicine Inc. (CMND) Form 6-K — Jul 16, 2026
Clearmind Medicine reported positive ex vivo mucoadhesion results for its intranasal formulation of MEAI, demonstrating markedly improved nasal residence characteristics compared with a standard solution. The study, which utilized freshly isolated rabbit nasal mucosa, showed the intranasal formulation consistently maintained a greater proportion of the initially adhered dose over a 30-minute period, validating the company's platform to overcome rapid mucociliary clearance.
Key figures
- Granted Patents
- 32
- Patent Families
- 19
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.